Lilly shares seen down on clot drug worry-Barron's

NEW YORK, Nov 18 (Reuters) - Shares of Eli Lilly and Co (LLY.N) could dip another 10 percent as mixed results for its anti-clotting drug dim the company's sales outlook, according to financial newspaper Barron's.

Patients on Lilly's drug suffered fewer heart attacks and strokes than those using its competitor, Bristol-Myers Squibb Co's (BMY.N) Plavix, but they bled more, some fatally. Though Lilly's drug will likely reach the market, doctors may be too concerned about the bleeding to make it Lilly's next blockbuster, Barron's said.

(Reporting by Lisa Lee; Editing by Braden Reddall)

((Reuters Messaging: lisa.lee.reuters.com@reuters.net; +1 646 223 6129)) Keywords: LILLY SHARES/BARRON'S

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nN18407921